1 Report Overview 1.1 Study Scope 1.2 Market Analysis by Type 1.2.1 Global Hepatocellular Carcinoma Targeted Drug Market Size Growth Rate by Type: 2018 VS 2022 VS 2029 1.2.2 Sorafenib 1.2.3 Lenvatinib 1.2.4 Regorafenib 1.2.5 Other 1.3 Market by Application 1.3.1 Global Hepatocellular Carcinoma Targeted Drug Market Growth by Application: 2018 VS 2022 VS 2029 1.3.2 Hospital 1.3.3 Retail Pharmacy 1.3.4 Other 1.4 Study Objectives 1.5 Years Considered 1.6 Years Considered 2 Global Growth Trends 2.1 Global Hepatocellular Carcinoma Targeted Drug Market Perspective (2018-2029) 2.2 Hepatocellular Carcinoma Targeted Drug Growth Trends by Region 2.2.1 Global Hepatocellular Carcinoma Targeted Drug Market Size by Region: 2018 VS 2022 VS 2029 2.2.2 Hepatocellular Carcinoma Targeted Drug Historic Market Size by Region (2018-2023) 2.2.3 Hepatocellular Carcinoma Targeted Drug Forecasted Market Size by Region (2024-2029) 2.3 Hepatocellular Carcinoma Targeted Drug Market Dynamics 2.3.1 Hepatocellular Carcinoma Targeted Drug Industry Trends 2.3.2 Hepatocellular Carcinoma Targeted Drug Market Drivers 2.3.3 Hepatocellular Carcinoma Targeted Drug Market Challenges 2.3.4 Hepatocellular Carcinoma Targeted Drug Market Restraints 3 Competition Landscape by Key Players 3.1 Global Top Hepatocellular Carcinoma Targeted Drug Players by Revenue 3.1.1 Global Top Hepatocellular Carcinoma Targeted Drug Players by Revenue (2018-2023) 3.1.2 Global Hepatocellular Carcinoma Targeted Drug Revenue Market Share by Players (2018-2023) 3.2 Global Hepatocellular Carcinoma Targeted Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3) 3.3 Players Covered: Ranking by Hepatocellular Carcinoma Targeted Drug Revenue 3.4 Global Hepatocellular Carcinoma Targeted Drug Market Concentration Ratio 3.4.1 Global Hepatocellular Carcinoma Targeted Drug Market Concentration Ratio (CR5 and HHI) 3.4.2 Global Top 10 and Top 5 Companies by Hepatocellular Carcinoma Targeted Drug Revenue in 2022 3.5 Hepatocellular Carcinoma Targeted Drug Key Players Head office and Area Served 3.6 Key Players Hepatocellular Carcinoma Targeted Drug Product Solution and Service 3.7 Date of Enter into Hepatocellular Carcinoma Targeted Drug Market 3.8 Mergers & Acquisitions, Expansion Plans 4 Hepatocellular Carcinoma Targeted Drug Breakdown Data by Type 4.1 Global Hepatocellular Carcinoma Targeted Drug Historic Market Size by Type (2018-2023) 4.2 Global Hepatocellular Carcinoma Targeted Drug Forecasted Market Size by Type (2024-2029) 5 Hepatocellular Carcinoma Targeted Drug Breakdown Data by Application 5.1 Global Hepatocellular Carcinoma Targeted Drug Historic Market Size by Application (2018-2023) 5.2 Global Hepatocellular Carcinoma Targeted Drug Forecasted Market Size by Application (2024-2029) 6 North America 6.1 North America Hepatocellular Carcinoma Targeted Drug Market Size (2018-2029) 6.2 North America Hepatocellular Carcinoma Targeted Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029 6.3 North America Hepatocellular Carcinoma Targeted Drug Market Size by Country (2018-2023) 6.4 North America Hepatocellular Carcinoma Targeted Drug Market Size by Country (2024-2029) 6.5 United States 6.6 Canada 7 Europe 7.1 Europe Hepatocellular Carcinoma Targeted Drug Market Size (2018-2029) 7.2 Europe Hepatocellular Carcinoma Targeted Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029 7.3 Europe Hepatocellular Carcinoma Targeted Drug Market Size by Country (2018-2023) 7.4 Europe Hepatocellular Carcinoma Targeted Drug Market Size by Country (2024-2029) 7.5 Germany 7.6 France 7.7 U.K. 7.8 Italy 7.9 Russia 7.10 Nordic Countries 8 Asia-Pacific 8.1 Asia-Pacific Hepatocellular Carcinoma Targeted Drug Market Size (2018-2029) 8.2 Asia-Pacific Hepatocellular Carcinoma Targeted Drug Market Growth Rate by Region: 2018 VS 2022 VS 2029 8.3 Asia-Pacific Hepatocellular Carcinoma Targeted Drug Market Size by Region (2018-2023) 8.4 Asia-Pacific Hepatocellular Carcinoma Targeted Drug Market Size by Region (2024-2029) 8.5 China 8.6 Japan 8.7 South Korea 8.8 Southeast Asia 8.9 India 8.10 Australia 9 Latin America 9.1 Latin America Hepatocellular Carcinoma Targeted Drug Market Size (2018-2029) 9.2 Latin America Hepatocellular Carcinoma Targeted Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029 9.3 Latin America Hepatocellular Carcinoma Targeted Drug Market Size by Country (2018-2023) 9.4 Latin America Hepatocellular Carcinoma Targeted Drug Market Size by Country (2024-2029) 9.5 Mexico 9.6 Brazil 10 Middle East & Africa 10.1 Middle East & Africa Hepatocellular Carcinoma Targeted Drug Market Size (2018-2029) 10.2 Middle East & Africa Hepatocellular Carcinoma Targeted Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029 10.3 Middle East & Africa Hepatocellular Carcinoma Targeted Drug Market Size by Country (2018-2023) 10.4 Middle East & Africa Hepatocellular Carcinoma Targeted Drug Market Size by Country (2024-2029) 10.5 Turkey 10.6 Saudi Arabia 10.7 UAE 11 Key Players Profiles 11.1 Bayer 11.1.1 Bayer Company Detail 11.1.2 Bayer Business Overview 11.1.3 Bayer Hepatocellular Carcinoma Targeted Drug Introduction 11.1.4 Bayer Revenue in Hepatocellular Carcinoma Targeted Drug Business (2018-2023) 11.1.5 Bayer Recent Development 11.2 Eisai 11.2.1 Eisai Company Detail 11.2.2 Eisai Business Overview 11.2.3 Eisai Hepatocellular Carcinoma Targeted Drug Introduction 11.2.4 Eisai Revenue in Hepatocellular Carcinoma Targeted Drug Business (2018-2023) 11.2.5 Eisai Recent Development 11.3 Zelgen 11.3.1 Zelgen Company Detail 11.3.2 Zelgen Business Overview 11.3.3 Zelgen Hepatocellular Carcinoma Targeted Drug Introduction 11.3.4 Zelgen Revenue in Hepatocellular Carcinoma Targeted Drug Business (2018-2023) 11.3.5 Zelgen Recent Development 11.4 Cipla 11.4.1 Cipla Company Detail 11.4.2 Cipla Business Overview 11.4.3 Cipla Hepatocellular Carcinoma Targeted Drug Introduction 11.4.4 Cipla Revenue in Hepatocellular Carcinoma Targeted Drug Business (2018-2023) 11.4.5 Cipla Recent Development 11.5 Natco Pharma 11.5.1 Natco Pharma Company Detail 11.5.2 Natco Pharma Business Overview 11.5.3 Natco Pharma Hepatocellular Carcinoma Targeted Drug Introduction 11.5.4 Natco Pharma Revenue in Hepatocellular Carcinoma Targeted Drug Business (2018-2023) 11.5.5 Natco Pharma Recent Development 11.6 BEACON Pharma 11.6.1 BEACON Pharma Company Detail 11.6.2 BEACON Pharma Business Overview 11.6.3 BEACON Pharma Hepatocellular Carcinoma Targeted Drug Introduction 11.6.4 BEACON Pharma Revenue in Hepatocellular Carcinoma Targeted Drug Business (2018-2023) 11.6.5 BEACON Pharma Recent Development 11.7 Jiangxi Shanxiang 11.7.1 Jiangxi Shanxiang Company Detail 11.7.2 Jiangxi Shanxiang Business Overview 11.7.3 Jiangxi Shanxiang Hepatocellular Carcinoma Targeted Drug Introduction 11.7.4 Jiangxi Shanxiang Revenue in Hepatocellular Carcinoma Targeted Drug Business (2018-2023) 11.7.5 Jiangxi Shanxiang Recent Development 11.8 Yao Pharma 11.8.1 Yao Pharma Company Detail 11.8.2 Yao Pharma Business Overview 11.8.3 Yao Pharma Hepatocellular Carcinoma Targeted Drug Introduction 11.8.4 Yao Pharma Revenue in Hepatocellular Carcinoma Targeted Drug Business (2018-2023) 11.8.5 Yao Pharma Recent Development 11.9 CSPC 11.9.1 CSPC Company Detail 11.9.2 CSPC Business Overview 11.9.3 CSPC Hepatocellular Carcinoma Targeted Drug Introduction 11.9.4 CSPC Revenue in Hepatocellular Carcinoma Targeted Drug Business (2018-2023) 11.9.5 CSPC Recent Development 11.10 CHIATAI Tianqing 11.10.1 CHIATAI Tianqing Company Detail 11.10.2 CHIATAI Tianqing Business Overview 11.10.3 CHIATAI Tianqing Hepatocellular Carcinoma Targeted Drug Introduction 11.10.4 CHIATAI Tianqing Revenue in Hepatocellular Carcinoma Targeted Drug Business (2018-2023) 11.10.5 CHIATAI Tianqing Recent Development 11.11 Simcere 11.11.1 Simcere Company Detail 11.11.2 Simcere Business Overview 11.11.3 Simcere Hepatocellular Carcinoma Targeted Drug Introduction 11.11.4 Simcere Revenue in Hepatocellular Carcinoma Targeted Drug Business (2018-2023) 11.11.5 Simcere Recent Development 12 Analyst's Viewpoints/Conclusions 13 Appendix 13.1 Research Methodology 13.1.1 Methodology/Research Approach 13.1.2 Data Source 13.2 Disclaimer 13.3 Author Details

List of Tables Table 1. Global Hepatocellular Carcinoma Targeted Drug Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029 Table 2. Key Players of Sorafenib Table 3. Key Players of Lenvatinib Table 4. Key Players of Regorafenib Table 5. Key Players of Other Table 6. Global Hepatocellular Carcinoma Targeted Drug Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029 Table 7. Global Hepatocellular Carcinoma Targeted Drug Market Size by Region (US$ Million): 2018 VS 2022 VS 2029 Table 8. Global Hepatocellular Carcinoma Targeted Drug Market Size by Region (2018-2023) & (US$ Million) Table 9. Global Hepatocellular Carcinoma Targeted Drug Market Share by Region (2018-2023) Table 10. Global Hepatocellular Carcinoma Targeted Drug Forecasted Market Size by Region (2024-2029) & (US$ Million) Table 11. Global Hepatocellular Carcinoma Targeted Drug Market Share by Region (2024-2029) Table 12. Hepatocellular Carcinoma Targeted Drug Market Trends Table 13. Hepatocellular Carcinoma Targeted Drug Market Drivers Table 14. Hepatocellular Carcinoma Targeted Drug Market Challenges Table 15. Hepatocellular Carcinoma Targeted Drug Market Restraints Table 16. Global Hepatocellular Carcinoma Targeted Drug Revenue by Players (2018-2023) & (US$ Million) Table 17. Global Hepatocellular Carcinoma Targeted Drug Market Share by Players (2018-2023) Table 18. Global Top Hepatocellular Carcinoma Targeted Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hepatocellular Carcinoma Targeted Drug as of 2022) Table 19. Ranking of Global Top Hepatocellular Carcinoma Targeted Drug Companies by Revenue (US$ Million) in 2022 Table 20. Global 5 Largest Players Market Share by Hepatocellular Carcinoma Targeted Drug Revenue (CR5 and HHI) & (2018-2023) Table 21. Key Players Headquarters and Area Served Table 22. Key Players Hepatocellular Carcinoma Targeted Drug Product Solution and Service Table 23. Date of Enter into Hepatocellular Carcinoma Targeted Drug Market Table 24. Mergers & Acquisitions, Expansion Plans Table 25. Global Hepatocellular Carcinoma Targeted Drug Market Size by Type (2018-2023) & (US$ Million) Table 26. Global Hepatocellular Carcinoma Targeted Drug Revenue Market Share by Type (2018-2023) Table 27. Global Hepatocellular Carcinoma Targeted Drug Forecasted Market Size by Type (2024-2029) & (US$ Million) Table 28. Global Hepatocellular Carcinoma Targeted Drug Revenue Market Share by Type (2024-2029) Table 29. Global Hepatocellular Carcinoma Targeted Drug Market Size by Application (2018-2023) & (US$ Million) Table 30. Global Hepatocellular Carcinoma Targeted Drug Revenue Market Share by Application (2018-2023) Table 31. Global Hepatocellular Carcinoma Targeted Drug Forecasted Market Size by Application (2024-2029) & (US$ Million) Table 32. Global Hepatocellular Carcinoma Targeted Drug Revenue Market Share by Application (2024-2029) Table 33. North America Hepatocellular Carcinoma Targeted Drug Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029 Table 34. North America Hepatocellular Carcinoma Targeted Drug Market Size by Country (2018-2023) & (US$ Million) Table 35. North America Hepatocellular Carcinoma Targeted Drug Market Size by Country (2024-2029) & (US$ Million) Table 36. Europe Hepatocellular Carcinoma Targeted Drug Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029 Table 37. Europe Hepatocellular Carcinoma Targeted Drug Market Size by Country (2018-2023) & (US$ Million) Table 38. Europe Hepatocellular Carcinoma Targeted Drug Market Size by Country (2024-2029) & (US$ Million) Table 39. Asia-Pacific Hepatocellular Carcinoma Targeted Drug Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029 Table 40. Asia-Pacific Hepatocellular Carcinoma Targeted Drug Market Size by Region (2018-2023) & (US$ Million) Table 41. Asia-Pacific Hepatocellular Carcinoma Targeted Drug Market Size by Region (2024-2029) & (US$ Million) Table 42. Latin America Hepatocellular Carcinoma Targeted Drug Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029 Table 43. Latin America Hepatocellular Carcinoma Targeted Drug Market Size by Country (2018-2023) & (US$ Million) Table 44. Latin America Hepatocellular Carcinoma Targeted Drug Market Size by Country (2024-2029) & (US$ Million) Table 45. Middle East & Africa Hepatocellular Carcinoma Targeted Drug Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029 Table 46. Middle East & Africa Hepatocellular Carcinoma Targeted Drug Market Size by Country (2018-2023) & (US$ Million) Table 47. Middle East & Africa Hepatocellular Carcinoma Targeted Drug Market Size by Country (2024-2029) & (US$ Million) Table 48. Bayer Company Detail Table 49. Bayer Business Overview Table 50. Bayer Hepatocellular Carcinoma Targeted Drug Product Table 51. Bayer Revenue in Hepatocellular Carcinoma Targeted Drug Business (2018-2023) & (US$ Million) Table 52. Bayer Recent Development Table 53. Eisai Company Detail Table 54. Eisai Business Overview Table 55. Eisai Hepatocellular Carcinoma Targeted Drug Product Table 56. Eisai Revenue in Hepatocellular Carcinoma Targeted Drug Business (2018-2023) & (US$ Million) Table 57. Eisai Recent Development Table 58. Zelgen Company Detail Table 59. Zelgen Business Overview Table 60. Zelgen Hepatocellular Carcinoma Targeted Drug Product Table 61. Zelgen Revenue in Hepatocellular Carcinoma Targeted Drug Business (2018-2023) & (US$ Million) Table 62. Zelgen Recent Development Table 63. Cipla Company Detail Table 64. Cipla Business Overview Table 65. Cipla Hepatocellular Carcinoma Targeted Drug Product Table 66. Cipla Revenue in Hepatocellular Carcinoma Targeted Drug Business (2018-2023) & (US$ Million) Table 67. Cipla Recent Development Table 68. Natco Pharma Company Detail Table 69. Natco Pharma Business Overview Table 70. Natco Pharma Hepatocellular Carcinoma Targeted Drug Product Table 71. Natco Pharma Revenue in Hepatocellular Carcinoma Targeted Drug Business (2018-2023) & (US$ Million) Table 72. Natco Pharma Recent Development Table 73. BEACON Pharma Company Detail Table 74. BEACON Pharma Business Overview Table 75. BEACON Pharma Hepatocellular Carcinoma Targeted Drug Product Table 76. BEACON Pharma Revenue in Hepatocellular Carcinoma Targeted Drug Business (2018-2023) & (US$ Million) Table 77. BEACON Pharma Recent Development Table 78. Jiangxi Shanxiang Company Detail Table 79. Jiangxi Shanxiang Business Overview Table 80. Jiangxi Shanxiang Hepatocellular Carcinoma Targeted Drug Product Table 81. Jiangxi Shanxiang Revenue in Hepatocellular Carcinoma Targeted Drug Business (2018-2023) & (US$ Million) Table 82. Jiangxi Shanxiang Recent Development Table 83. Yao Pharma Company Detail Table 84. Yao Pharma Business Overview Table 85. Yao Pharma Hepatocellular Carcinoma Targeted Drug Product Table 86. Yao Pharma Revenue in Hepatocellular Carcinoma Targeted Drug Business (2018-2023) & (US$ Million) Table 87. Yao Pharma Recent Development Table 88. CSPC Company Detail Table 89. CSPC Business Overview Table 90. CSPC Hepatocellular Carcinoma Targeted Drug Product Table 91. CSPC Revenue in Hepatocellular Carcinoma Targeted Drug Business (2018-2023) & (US$ Million) Table 92. CSPC Recent Development Table 93. CHIATAI Tianqing Company Detail Table 94. CHIATAI Tianqing Business Overview Table 95. CHIATAI Tianqing Hepatocellular Carcinoma Targeted Drug Product Table 96. CHIATAI Tianqing Revenue in Hepatocellular Carcinoma Targeted Drug Business (2018-2023) & (US$ Million) Table 97. CHIATAI Tianqing Recent Development Table 98. Simcere Company Detail Table 99. Simcere Business Overview Table 100. Simcere Hepatocellular Carcinoma Targeted Drug Product Table 101. Simcere Revenue in Hepatocellular Carcinoma Targeted Drug Business (2018-2023) & (US$ Million) Table 102. Simcere Recent Development Table 103. Research Programs/Design for This Report Table 104. Key Data Information from Secondary Sources Table 105. Key Data Information from Primary Sources List of Figures Figure 1. Global Hepatocellular Carcinoma Targeted Drug Market Size Comparison by Type (2023-2029) & (US$ Million) Figure 2. Global Hepatocellular Carcinoma Targeted Drug Market Share by Type: 2022 VS 2029 Figure 3. Sorafenib Features Figure 4. Lenvatinib Features Figure 5. Regorafenib Features Figure 6. Other Features Figure 7. Global Hepatocellular Carcinoma Targeted Drug Market Size Comparison by Application (2023-2029) & (US$ Million) Figure 8. Global Hepatocellular Carcinoma Targeted Drug Market Share by Application: 2022 VS 2029 Figure 9. Hospital Case Studies Figure 10. Retail Pharmacy Case Studies Figure 11. Other Case Studies Figure 12. Hepatocellular Carcinoma Targeted Drug Report Years Considered Figure 13. Global Hepatocellular Carcinoma Targeted Drug Market Size (US$ Million), Year-over-Year: 2018-2029 Figure 14. Global Hepatocellular Carcinoma Targeted Drug Market Size, (US$ Million), 2018 VS 2022 VS 2029 Figure 15. Global Hepatocellular Carcinoma Targeted Drug Market Share by Region: 2022 VS 2029 Figure 16. Global Hepatocellular Carcinoma Targeted Drug Market Share by Players in 2022 Figure 17. Global Top Hepatocellular Carcinoma Targeted Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hepatocellular Carcinoma Targeted Drug as of 2022) Figure 18. The Top 10 and 5 Players Market Share by Hepatocellular Carcinoma Targeted Drug Revenue in 2022 Figure 19. North America Hepatocellular Carcinoma Targeted Drug Market Size YoY Growth (2018-2029) & (US$ Million) Figure 20. North America Hepatocellular Carcinoma Targeted Drug Market Share by Country (2018-2029) Figure 21. United States Hepatocellular Carcinoma Targeted Drug Market Size YoY Growth (2018-2029) & (US$ Million) Figure 22. Canada Hepatocellular Carcinoma Targeted Drug Market Size YoY Growth (2018-2029) & (US$ Million) Figure 23. Europe Hepatocellular Carcinoma Targeted Drug Market Size YoY Growth (2018-2029) & (US$ Million) Figure 24. Europe Hepatocellular Carcinoma Targeted Drug Market Share by Country (2018-2029) Figure 25. Germany Hepatocellular Carcinoma Targeted Drug Market Size YoY Growth (2018-2029) & (US$ Million) Figure 26. France Hepatocellular Carcinoma Targeted Drug Market Size YoY Growth (2018-2029) & (US$ Million) Figure 27. U.K. Hepatocellular Carcinoma Targeted Drug Market Size YoY Growth (2018-2029) & (US$ Million) Figure 28. Italy Hepatocellular Carcinoma Targeted Drug Market Size YoY Growth (2018-2029) & (US$ Million) Figure 29. Russia Hepatocellular Carcinoma Targeted Drug Market Size YoY Growth (2018-2029) & (US$ Million) Figure 30. Nordic Countries Hepatocellular Carcinoma Targeted Drug Market Size YoY Growth (2018-2029) & (US$ Million) Figure 31. Asia-Pacific Hepatocellular Carcinoma Targeted Drug Market Size YoY Growth (2018-2029) & (US$ Million) Figure 32. Asia-Pacific Hepatocellular Carcinoma Targeted Drug Market Share by Region (2018-2029) Figure 33. China Hepatocellular Carcinoma Targeted Drug Market Size YoY Growth (2018-2029) & (US$ Million) Figure 34. Japan Hepatocellular Carcinoma Targeted Drug Market Size YoY Growth (2018-2029) & (US$ Million) Figure 35. South Korea Hepatocellular Carcinoma Targeted Drug Market Size YoY Growth (2018-2029) & (US$ Million) Figure 36. Southeast Asia Hepatocellular Carcinoma Targeted Drug Market Size YoY Growth (2018-2029) & (US$ Million) Figure 37. India Hepatocellular Carcinoma Targeted Drug Market Size YoY Growth (2018-2029) & (US$ Million) Figure 38. Australia Hepatocellular Carcinoma Targeted Drug Market Size YoY Growth (2018-2029) & (US$ Million) Figure 39. Latin America Hepatocellular Carcinoma Targeted Drug Market Size YoY Growth (2018-2029) & (US$ Million) Figure 40. Latin America Hepatocellular Carcinoma Targeted Drug Market Share by Country (2018-2029) Figure 41. Mexico Hepatocellular Carcinoma Targeted Drug Market Size YoY Growth (2018-2029) & (US$ Million) Figure 42. Brazil Hepatocellular Carcinoma Targeted Drug Market Size YoY Growth (2018-2029) & (US$ Million) Figure 43. Middle East & Africa Hepatocellular Carcinoma Targeted Drug Market Size YoY Growth (2018-2029) & (US$ Million) Figure 44. Middle East & Africa Hepatocellular Carcinoma Targeted Drug Market Share by Country (2018-2029) Figure 45. Turkey Hepatocellular Carcinoma Targeted Drug Market Size YoY Growth (2018-2029) & (US$ Million) Figure 46. Saudi Arabia Hepatocellular Carcinoma Targeted Drug Market Size YoY Growth (2018-2029) & (US$ Million) Figure 47. Bayer Revenue Growth Rate in Hepatocellular Carcinoma Targeted Drug Business (2018-2023) Figure 48. Eisai Revenue Growth Rate in Hepatocellular Carcinoma Targeted Drug Business (2018-2023) Figure 49. Zelgen Revenue Growth Rate in Hepatocellular Carcinoma Targeted Drug Business (2018-2023) Figure 50. Cipla Revenue Growth Rate in Hepatocellular Carcinoma Targeted Drug Business (2018-2023) Figure 51. Natco Pharma Revenue Growth Rate in Hepatocellular Carcinoma Targeted Drug Business (2018-2023) Figure 52. BEACON Pharma Revenue Growth Rate in Hepatocellular Carcinoma Targeted Drug Business (2018-2023) Figure 53. Jiangxi Shanxiang Revenue Growth Rate in Hepatocellular Carcinoma Targeted Drug Business (2018-2023) Figure 54. Yao Pharma Revenue Growth Rate in Hepatocellular Carcinoma Targeted Drug Business (2018-2023) Figure 55. CSPC Revenue Growth Rate in Hepatocellular Carcinoma Targeted Drug Business (2018-2023) Figure 56. CHIATAI Tianqing Revenue Growth Rate in Hepatocellular Carcinoma Targeted Drug Business (2018-2023) Figure 57. Simcere Revenue Growth Rate in Hepatocellular Carcinoma Targeted Drug Business (2018-2023) Figure 58. Bottom-up and Top-down Approaches for This Report Figure 59. Data Triangulation Figure 60. Key Executives Interviewed

Bayer Eisai Zelgen Cipla Natco Pharma BEACON Pharma Jiangxi Shanxiang Yao Pharma CSPC CHIATAI Tianqing Simcere